estim move
report limit sole use client wolf research pleas refer disclosur section locat end report analyst
certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc
materi reduc est move recessionari assumpt
cut estim lower estim lh reflect disrupt lower
estim reflect recessionari assumpt princip weaker volum growth lower patient collect
estim also reflect chang medicar reimburs pama sequestr test volum
sg save adjust capit deploy assumpt ex pama time forward ep estim decreas
consensu valuat revis histor averag
absolut rel said area healthcar servic believ justifi extrem
low visibl next quarter host webcast friday review latest thought
dgx volum declin consist w/ datapoint dgx volum declin second half march
gener consist datapoint track recent day recent seen data suggest
physician offic visit mid-march justin lake not-for-profit insur contact seen declin
claim rang assum elect servic cost would indic elect
also withdrew guidanc cite declin procedur volum past coupl week
assumpt model core lab volum quarter leav core lab volum
full year decrement margin impli reduct lab ebit
margin busi even larger impact ep given financi leverag
consid impact test sg reduct sequestr holiday patient collect ep
estim estim lh
recess assumpt estim reflect recessionari assumpt assum lab volum
previou estim assum patient collect decreas vs current level lh covanc
segment assum ebit previou est sg assum initi benefit
cost cut model sustain also adjust recent delay pama reimburs
cut net chang ep estim decreas ex pama time compani
target price year-end target price goe downsid target price lh goe
downsid target multipl lh price-to-earnings respect exclud
pama delay benefit ep valuat purpos put simpli difficulti justifi premium hc
subsector distributor manag care given unpreced level nt uncertainti face lab
compani data factset wolf research llc
note total return reflect annual dividend yield compar year-end price target
compani data factset wolf research llc
laboratori corp america lh year-end price rel price dividend rel dividend total rel analyst analyst analyst ep ex pama lab wolf research estim chang
compani data factset wolf research llc
rel price return xlv
compani data factset wolf research llc
relativelh rel updat util datapoint
withdraw guidanc provid updat trend
issu press releas withdraw guidanc result advers impact
pandem oper result
compani note volum declin last two week march inclus test
expect materi declin
specif headwind call includ signific reduct physician offic visit cancel elect medic
procedur custom close sever curtail servic adopt work-from-hom shelter-in-plac
also disclos current perform test per day
compani oper result januari februari consist guidanc full year provid januari
howev march compani experienc anticip continu experi materi declin test volum due
pandem last two week march volum declin excess inclus test feder state
local government polici initi design reduc transmiss result among thing signific
reduct physician offic visit cancel elect medic procedur custom close sever curtail oper
voluntarili respons govern order adopt work-from-hom shelter-in-plac polici
believ continu impact compani oper result cash flow financi condit possibl
compani experi advers impact cash collect custom client payer result impact
compani believ advers impact oper result cash flow and/or financi condit primarili driven
sever durat pandem pandem impact healthcar system economi
time scope effect feder state local government respons pandem primari driver
beyond compani knowledg control result time compani reason estim advers impact
pandem busi oper result cash flow and/or financi condit advers impact like
materi compani therefor withdraw previous announc guidanc full year
compani data factset wolf research llc
estim impact second half march
estim test tailwind volum growth second half march
correct would put core volum declin vs all-in declin note
estim tailwind march volum thousand
compani report wolf research llc
estim test perform per day second half second half test perform second half requisit requisit volum per second half requisit volum second half march y/i volum contribut updat consist earli data point
volum januari februari line
expect experienc declin earli march
declin last two week march ex covid-
test estim declin
withdrew guidanc
januari februari perform ahead
volum declin recent week
data anecdot
come across data suggest physician
offic visit mid-march
anecdot evid physician offic anticip
earli datapoint not-for-profit plan see
declin claim rang
assum elect servic cost
would indic elect
compani data factset wolf research llc
physician offic visit face high risk deferr substitut
overal physician offic visit drive lab volum less urgent mani area healthcar util
accord cdc doctor visit prevent care would appear face high risk deferr
categori would also appear risk deferr substitut telehealth
major reason office-bas physician visit
compani data factset wolf research llc
volum assumpt estim
note flag excess second half march sever major citi unfortun
appear escal toward nyc-lik outbreak
assum core lab volum quarter would leav lab revenu full
volum assumpt separ assumpt around benefit test
y/i volum headwind disrupt assum scenario analysi
compani data factset wolf research llc
test assumpt
provid cumul test figur note run test per day
assum daili averag closer march ramp test capac
assum test per day run test per day run
assumpt result increment revenu ebit assum increment margin
test assumpt assum estim
compani data factset wolf research llc
test per day compani test compani reimburs revenu margin lh test assumpt
lh perform test impli test per day period lh
assum test per day run test per day run
assumpt result increment revenu ebit assum increment margin
lh updat test volum
test assumpt assum estim lh
compani data factset wolf research llc
test per day oper test reimburs revenu margin scenario analysi assumpt
lab collect almost revenu patient
assum collect decreas remain volum
produc ep headwind compani
assum revenu headwind vs lh initi guidanc
decrement margin lost revenu
would reduc covanc ebit estim almost
assum compani reduc sg vs initi guidanc
note lab alreadi oper cost reduct program
deal pama pressur
boost medicar payment may decemb
medicar make revenu lh lab revenu
remov model
compani data factset wolf research llc
ep bridg lh
compani data factset wolf research llc
epslow lab volum due reduct lab volum revenu decrement marginshigh bad reduct patient collect remaind yearincrement sg sg assumpt detailedsequestr increas medicar revenu revenu like impact share repurchas modelcurr epslow lab volum due reduct lab volum revenu decrement marginshigh bad reduct patient collect remaind yearincrement sg sg assumpt detailedsequestr increas medicar revenu reduct revenu decrement marginsshar share repurchas modelcurr move recessionari assumpt
may differ vs prior recess lab
lab collect almost revenu patient
lead financi crisi
recent year lab alreadi oper cost reduct program
deal pama reimburs pressur may find increment cut
difficult realiz
gene-bas
categori grew much faster routin test busi lead
financi crisi remain fairli strong help off-set
pressur routin test
today growth slower
given coverag provis insur coverag
durabl previou recess
compani data factset wolf research llc
lab rel higher exposur patient collect
averag lh gener lab revenu insur govern medicar medicaid
directli patient
exposur patient revenu significantli higher healthcar provid
view leav lh poorli posit materi econom slowdown
lh lab payer mix
lh lab payer mix billion
compani data factset wolf research llc
enrol high-deduct health plan grown significantli
employe enrol high-deduct plan financi crisi
employe mention health exchang enrolle enrol high-deduct plan today
market share employ health plan
kaiser famili foundat wolf research llc
averag deduct singl coverag gone sinc
averag deduct singl coverag
kaiser famili foundat wolf research llc
exposur patient collect larger financi crisi
earn call
remind us percent revenu co-pay deduct
think probabl realli embed call third parti
look look revenu payor embed third parti co-pay deduct
see patient uninsur bill directli
exposur patient pay financi crisi vs current
compani data factset wolf research llc
crisiscurr earn sensit patient collect
estim reduct patient lab revenu would repres ep headwind headwind
lh
previous said patient concess annual impli collect rate
 lh exposur reduct patient revenu
compani data factset wolf research llc
dgxlhlab revenu lab revenu patient lab revenu patient impact weekli initi jobless claim crisi high
new york time compani data factset wolf research llc
drug abus test procycl
estim drug abus employ screen test make lab revenu procycl
take cumul view drug abus test still significantli level
drug abus test y/i growth
drug abus test stack growth
compani data factset wolf research llc
sg alreadi area focu lab
recent year lab alreadi oper cost reduct program deal pama reimburs pressur
may find increment cut difficult realiz averag compani
compani report wolf research llc
growthrevenu growthsg growthrevenu growthsg growth pama cut delay year deserv win industri
driven pama year
see well-deserv win
industri step
plate ramp
test capac like
lost util result
social distanc shelter place
assum stimulu bill
pass hous sign
law last
year pama reimburs cut
requir current data
compani data factset wolf research llc
assumpt estim
assum lab volum previou estim
assum collect decreas remain volum vs
level produc ep headwind compani
assum lab see test
assum ebit previou est
assum initi benefit cost cut
sustain
compani data factset wolf research llc
bridg previou estim current estim
compani data factset wolf research llc
epslow lab volum due assumpt detailedlow lab volum due volum previou estimateshigh bad reduct patient collect increment sg sg save assumpt detail assum continu increas medicar revenu monthspama delay pama revenu like impact share repurchas lower share price assumptioncurr estim ex pama ex pama epslow lab volum due assumpt detailedlow lab volum due volum previou estimateshigh bad reduct patient collect increment sg sg save assumpt detail assum continu increas medicar revenu monthspama delay pama assumpt detailedshar share repurchas lower share price assumptioncurr estim ex pama ex pama pama pressur may lead consolid
hospit outreach lab smaller independ lab compet lh referr physician
protect access medicar act pama like headwind entir lab
industri silver line lh would lab forc consid sell shut
expect acquisit add growth next sever year pama implement
notic move
base recent histori look pipelin
confid abl least
basi point compound-annual-growth-rate next sever year
without assumpt major move driven pama
term consolid abl plu
recent without get much traction yet pama
think start see deal flow base
hospit outreach smaller lab come realiz
enough scale think
busi long term former lh ceo david king
compani data factset wolf research llc
lab continu exposur hc servic debat
clinic lab littl exposur key current
debat health care recent center
prescript drug spend medicare-for-al vs public
spend lab servic hospit physician
make health care spend help
lab uniqu coupl interest way
one place health care neg
price growth commerci payment rate well
medicar rate least pama fulli
pay-for would wildcard argument
made lab servic would becom best hous
bad neighborhood medicare-for-al enact
compani data factset wolf research llc
hospit privat residenti medic leverag liquid
leverag focu increas materi
base estim net leverag peak lh net leverag peak
simplic metric hold net debt constant level
lh term loan leverag coven compani may need pay modest balanc seek waiver
net leverag base wr ebitda estim net debt
lh net leverag base wr ebitda estim net debt
compani data factset wolf research llc
given uncertain outlook cash flow year want assess compani current liquid
combin current cash avail capac exist credit facil access cash averag
cash flow oper past year lh access cash averag cash flow
note dgx cash adjust downward reflect januari march note matur
avail capac credit facil
compani data factset wolf research llc
note retir note januari anoth due march
lh debt matur note come novemb
long-term debt year matur
long-term debt year matur
factset wolf research llc
long-term debt valuat price
hc technolog distribut hc servic valuat
price-to-earnings healthcar technolog distribut compani
note multipl base current consensu estim price reflect close price
factset wolf research llc
hc technolog distribut hc servic valuat
ev ebitda healthcar technolog distribut compani
note multipl base current consensu estim price reflect close price
factset wolf research llc
rel price-to-earnings valuat lab subsector
rel price-to-earnings healthcar technolog distribut compani
note multipl assum earn estim wr portfolio strategi team price close
factset wolf research llc
year-end target price lh base price-to-earnings multipl respect
use wolf chief invest strategist chri senyek estim earn current
price-to-earnings multipl
impli rel target multipl lh
multipl absolut rel histor averag area coverag
justin lake healthcar servic coverag trade even larger discount
put simpli difficulti justifi premium healthcar subsector distributor manag care
given unpreced level near-term uncertainti face lab
note ep estim shown valuat purpos exclud delay pama reimburs cut
factset wolf research llc
laboratori corp america lh current rel rel rel rel rel price-to-earnings price-to-earnings price dividiend dividend rel diagnost current rel rel rel rel rel price-to-earnings price-to-earnings price dividiend dividend rel appendix addit valuat
compani data factset wolf research llc
compani data factset wolf research llc
compani data factset wolf research llc
compani data factset wolf research llc
price-to-earnings valuat absolut rel
ntm price-to-earnings multipl rel
compani data factset wolf research llc
p/erel price-to-earnings year year year year price-to-earnings year year year year ev/ebit valuat absolut rel
ntm ev/ebit multipl rel
compani data factset wolf research llc
forward ev/ebitrel ev/ebit year year year year ev/ebit year year year year ev/ebitda valuat absolut rel
ntm ev/ebitda multipl rel
compani data factset wolf research llc
